Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients
Brain, Behavior, and Immunity · 2025-02 · 124 · 115-122
DOI: 10.1016/j.bbi.2024.11.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025-02. Verfasst von J C Zwiep und 5 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, M…. Hauptthemen laut MEDLINE: Major Depressive Disorder. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organisation for Health Research and Development, Amsterdam Neuroscience, Brain Foundation.
Themen: Depression
Abstract (Originalsprache)
INTRODUCTION: Inflammatory and metabolic processes are linked to depression, but only 25-30% of depressed patients show low-grade inflammation and metabolic dysregulation associated with atypical, energy-related symptoms (AES). Interventions targeting immuno-metabolic dysregulation could benefit depressed patients, but currently no consensus exists how to best select patients with immuno-metabolic dysregulations. Therefore, we investigated which combinations of circulating C-reactive protein (CRP) and AES could identify those depressed individuals with significant immuno-metabolic dysregulation. METHODS: Data are from 1,077 persons with a current Major Depressive Disorder (MDD) of the Netherlands Study of Depression and Anxiety. Immuno-metabolic markers were Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNF-α), glycoprotein acetyls, body mass index (BMI), waist circumference, triglycerides, high-density-lipoprotein cholesterol (HDL cholesterol), glucose and leptin. Strata for CRP (≤ 1, 3 mg/L) and AES (score of ≤ 3, 4-5, ≥ 6) were compared on immuno-metabolic markers using analyses of covariance. RESULTS: Across strata of CRP and AES, there was a dose-response pattern with all higher immuno-metabolic marker levels across higher strata of CRP and AES, with the exception for an association between AES and TNF-α. Persons with both elevated CRP (> 1 mg/L) and high AES (≥ 6) showed a more dysregulated inflammatory and metabolic profile compared to persons with lower CRP and/or AES (p < 0.001). CONCLUSION: Our results show a dose-response relationship between both CRP levels and AES with immuno-metabolic risk biomarkers, indicating that CRP and AES combined can capture immuno-metabolic features of MDD. Combining these available and scalable indexes may be an effective strategy to select a patient sample with immuno-metabolic dysregulation who may benefit from treatments targeting inflammatory or metabolic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, Mental Health program, Amsterdam, the Netherlands. Electronic address:…
- Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, Mental Health program, Amsterdam, the Netherlands; Amsterdam Neuroscien…
- Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands; Department of Public Health and Primary Care, Health Campus The Hague, Leiden University Medical Center, The Hague, the Netherlands.
- Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, Mental Health program, Amsterdam, the Netherlands.
Förderung
- Netherlands Organisation for Health Research and Development
- Amsterdam Neuroscience
- Brain Foundation
- Amsterdam University Medical Centers
- Rijksuniversiteit Groningen
- Universiteit Leiden
Zitieren
APA
Zwiep, J. C., Milaneschi, Y., Giltay, E. J., Vinkers, C. H., Penninx, B. W. J. H., & Lamers, F. (2025). Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients. Brain, Behavior, and Immunity, 124, 115-122. https://doi.org/10.1016/j.bbi.2024.11.033
Vancouver
Zwiep JC, Milaneschi Y, Giltay EJ, Vinkers CH, Penninx BWJH, Lamers F. Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients. Brain, Behavior, and Immunity. 2025;124:115-122. doi:10.1016/j.bbi.2024.11.033
BibTeX
@article{Zwiep2025,
author = {Zwiep, J C and Milaneschi, Y and Giltay, E J and Vinkers, C H and Penninx, B W J H and Lamers, F},
title = {Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients},
journal = {Brain, Behavior, and Immunity},
year = {2025},
volume = {124},
pages = {115--122},
doi = {10.1016/j.bbi.2024.11.033}
}
EUVIMED